These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 33257690)

  • 1. Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant.
    Fichtner M; Bozkurt E; Salvucci M; McCann C; McAllister KA; Halang L; Düssmann H; Kinsella S; Crawford N; Sessler T; Longley DB; Prehn JHM
    Cell Death Dis; 2020 Nov; 11(11):1020. PubMed ID: 33257690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
    Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
    Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711.
    Crawford N; Salvucci M; Hellwig CT; Lincoln FA; Mooney RE; O'Connor CL; Prehn JH; Longley DB; Rehm M
    Cell Death Differ; 2018 Nov; 25(11):1952-1966. PubMed ID: 29500433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis.
    Xie X; Lee J; Liu H; Pearson T; Lu AY; Tripathy D; Devi GR; Bartholomeusz C; Ueno NT
    Mol Cancer Ther; 2021 Feb; 20(2):296-306. PubMed ID: 33323457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo.
    Zhou L; Zhang Y; Leng Y; Dai Y; Kmieciak M; Kramer L; Sharma K; Wang Y; Craun W; Grant S
    J Hematol Oncol; 2019 Mar; 12(1):25. PubMed ID: 30845975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.
    Krepler C; Chunduru SK; Halloran MB; He X; Xiao M; Vultur A; Villanueva J; Mitsuuchi Y; Neiman EM; Benetatos C; Nathanson KL; Amaravadi RK; Pehamberger H; McKinlay M; Herlyn M
    Clin Cancer Res; 2013 Apr; 19(7):1784-94. PubMed ID: 23403634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The non-peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis.
    Knoll G; Ehrenschwender M
    FEBS Open Bio; 2021 Mar; 11(3):714-723. PubMed ID: 33484626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway.
    Ding J; Qin D; Zhang Y; Li Q; Li Y; Li J
    Mol Med Rep; 2020 Mar; 21(3):1251-1257. PubMed ID: 31922244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC.
    Eytan DF; Snow GE; Carlson SG; Schiltz S; Chen Z; Van Waes C
    Laryngoscope; 2015 Mar; 125(3):E118-24. PubMed ID: 25431358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.
    Noonan AM; Bunch KP; Chen JQ; Herrmann MA; Lee JM; Kohn EC; O'Sullivan CC; Jordan E; Houston N; Takebe N; Kinders RJ; Cao L; Peer CJ; Figg WD; Annunziata CM
    Cancer; 2016 Feb; 122(4):588-597. PubMed ID: 26566079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia.
    Mak PY; Mak DH; Ruvolo V; Jacamo R; Kornblau SM; Kantarjian H; Andreeff M; Carter BZ
    Br J Haematol; 2014 Nov; 167(3):376-84. PubMed ID: 25079338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.
    Eytan DF; Snow GE; Carlson S; Derakhshan A; Saleh A; Schiltz S; Cheng H; Mohan S; Cornelius S; Coupar J; Sowers AL; Hernandez L; Mitchell JB; Annunziata CM; Chen Z; Van Waes C
    Cancer Res; 2016 Sep; 76(18):5442-5454. PubMed ID: 27469115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma.
    Amaravadi RK; Schilder RJ; Martin LP; Levin M; Graham MA; Weng DE; Adjei AA
    Mol Cancer Ther; 2015 Nov; 14(11):2569-75. PubMed ID: 26333381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.
    Brumatti G; Ma C; Lalaoui N; Nguyen NY; Navarro M; Tanzer MC; Richmond J; Ghisi M; Salmon JM; Silke N; Pomilio G; Glaser SP; de Valle E; Gugasyan R; Gurthridge MA; Condon SM; Johnstone RW; Lock R; Salvesen G; Wei A; Vaux DL; Ekert PG; Silke J
    Sci Transl Med; 2016 May; 8(339):339ra69. PubMed ID: 27194727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.
    Perimenis P; Galaris A; Voulgari A; Prassa M; Pintzas A
    BMC Cancer; 2016 Aug; 16():624. PubMed ID: 27520705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of birinapant in combination with carboplatin in targeting platinum‑resistant epithelial ovarian cancers.
    Singh T; Neal A; Dibernardo G; Raheseparian N; Moatamed NA; Memarzadeh S
    Int J Oncol; 2022 Mar; 60(3):. PubMed ID: 35191515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Divergent effect of Birinapant, and BV6 SMAC mimetic on TNFα induced NF-κB signaling and cell viability in activated hepatic stellate cells.
    Ghufran SM; Sharma S; Ghose S; Biswas S
    Mol Biol Rep; 2023 Mar; 50(3):2107-2117. PubMed ID: 36542236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
    Zakaria Z; Tivnan A; Flanagan L; Murray DW; Salvucci M; Stringer BW; Day BW; Boyd AW; Kögel D; Rehm M; O'Brien DF; Byrne AT; Prehn JH
    Br J Cancer; 2016 Jan; 114(2):188-98. PubMed ID: 26657652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.
    Carter BZ; Mak PY; Mak DH; Shi Y; Qiu Y; Bogenberger JM; Mu H; Tibes R; Yao H; Coombes KR; Jacamo RO; McQueen T; Kornblau SM; Andreeff M
    J Natl Cancer Inst; 2014 Feb; 106(2):djt440. PubMed ID: 24526787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.